Dexcom ONE+ Real-Time CGM Rolls Out in Europe

Dexcom has launched its next-generation Dexcom ONE+ real-time continuous glucose monitor (rt-CGM) for diabetes type 1 or 2 patients treating with insulin. Dexcom ONE+ is now available in Spain, Belgium, and Poland with a rollout next week in the Netherlands.
 
Dexcom ONE+ has three wear location options doesn’t need fingerpricks to measure blood glucose. Blood sugar readings can be shared with up to ten people. A first-in-class “delay first high” setting lets users set a time before which their sensor won’t alert them to a high glucose reading.
 
“In my conversations with Dexcom, I expressed the importance of CGM being easy to use for people with diabetes and their care teams. Dexcom ONE+ is now an all-in-one sensor, very easy to apply and use. This makes diabetes technology more accessible as it lowers the barrier to getting started,” said Dr. Liesbeth van Huffel, an endocrinologist at OLV Hospital Aalst in Belgium who focuses on diabetes tech.
 
Dr. van Huffel is part of a team conducting the Dexcom-funded ALERTT1 clinical trial, which is comparing rt-CGM to flash glucose monitoring in adult type 1 diabetes patients.
 
“Another important element was adding notes at certain moments, such as meals, insulin administration or sports activities,” Dr. van Huffel went on. “Compared to finger sticks, a CGM sensor provides a much clearer picture of how daily choices affect glucose levels. Dexcom sensors are known for their accuracy and reliability and now adding this note option to Dexcom ONE+ makes it even more transparent for the care team when coaching someone.”
 
The company also said Dexcom ONE+ has the top waterproof rating compared to competitive CGM brands; it can be submerged under 2.4 meters of water for up to 24 hours without failure when properly installed. The company expects to release Dexcom ONE+ in countries in Europe, the Middle East, and Africa in the coming months.
 
“Dexcom ONE+ incorporates our best-in-class technology and a range of features that we know will be well-received by the diabetes community,” said Dexcom’s executive VP and chief commercial officer Teri Lawver. “By building Dexcom ONE+ based on user and healthcare professional feedback we know we have a CGM system that is flexible, easy to get started with, and intuitive to use; a system that people with either Type 1 or Type 2 diabetes, and their care teams, can benefit from.”

Last month, the company broke ground on a new manufacturing facility in Athenry, Co. Galway. Dexcom expects the new facility to bring over 1,000 jobs to the area.